Minapharm Pharmaceuticals (CAI:MIPH) LT-Debt-to-Total-Asset: 0.13 (As of Dec. 2025)

What is Minapharm Pharmaceuticals LT-Debt-to-Total-Asset?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 LT-Debt-to-Total-Asset is 0.13 as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Minapharm Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.13.

Minapharm Pharmaceuticals's long-term debt to total assets ratio declined from Dec. 2024 (0.23) to Dec. 2025 (0.13). It may suggest that Minapharm Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Minapharm Pharmaceuticals (CAI:MIPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Minapharm Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Minapharm Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals LT-Debt-to-Total-Asset Chart

Minapharm Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

0.15

0.17

0.23

0.13

Minapharm Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.23	0.24	0.24	0.20	0.13

41GF Score

Minapharm Pharmaceuticals CAI:MIPH

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Minapharm Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Minapharm Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1762.999	/	13148.14
	=	0.13

Minapharm Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	1762.999	/	13148.14
	=	0.13

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.13 mean?

Minapharm Pharmaceuticals (CAI:MIPH) has a LT-Debt-to-Total-Asset of 0.13 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Minapharm Pharmaceuticals and its competitors.

Is Minapharm Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Minapharm Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.13. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Minapharm Pharmaceuticals' LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Minapharm Pharmaceuticals' LT-Debt-to-Total-Asset of 0.13 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Minapharm Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.13. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current LT-Debt-to-Total-Asset is 0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

LT-Debt-to-Total-Asset: 0.13
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CAI:NIPH CAI:RMDA CAI:PHAR XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY

Website https://www.minapharm.com

Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.

41GF Score

Get the complete analysis for CAI:MIPH

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08

Price

E£362.31

GF Value

View CAI:MIPH Analysis

See LT-Debt-to-Total-Asset data for all stocks →